



# Resource impact statement

Resource impact

Published: 27 February 2019

[www.nice.org.uk](http://www.nice.org.uk)

## No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).

This is because the technology is an option alongside current standard treatment options and the population size is small.

The list prices of encorafenib and binimetinib have discounts that are commercial in confidence. For enquiries about the patient access schemes please contact [PAS@pierre-fabre.com](mailto:PAS@pierre-fabre.com).

This technology is commissioned by NHS England. Providers are NHS hospital trusts.